Evaluating the Magrolimab-Based Triplet Combination in High-Risk AML

preview_player
Показать описание
According to results presented at the 2021 ASH Annual Meeting, the triplet combination of magrolimab plus azacitidine and venetoclax was safe, with high response rates reported in patients with newly diagnosed high-risk acute myeloid leukemia.
  1. Blood Cancers Today
  2. leukemia
  3. lymphoma
  4. myeloma
Рекомендации по теме
Evaluating the Magrolimab-Based 0:04:19

Evaluating the Magrolimab-Based Triplet Combination in High-Risk AML

ENHANCE-2 and ENHANCE-3: 0:01:35

ENHANCE-2 and ENHANCE-3: exploring magrolimab combinations in AML

Phase Ib/II study 0:02:44

Phase Ib/II study of magrolimab in combination with azacitidine and venetoclax in patients with AML

Uma Borate: Evaluating 0:04:32

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Novel combinations being 0:04:38

Novel combinations being explored in AML using an HMA-venetoclax backbone

Antibodies for the 0:01:24

Antibodies for the treatment of MDS: magrolimab & sabatolimab

Investigating the safety 0:03:50

Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with...

How can outcomes 0:08:37

How can outcomes be improved in patients with molecularly-defined high-risk AML?

Key updates in 0:02:00

Key updates in MDS from ASH on magrolimab, sabatolimab, venetoclax & tamibarotene

Advancing the management 0:47:01

Advancing the management of MDS and AML: Novel immune-based approaches

Updates from ASCO 0:55:38

Updates from ASCO and EHA Meeting 2022 about MDS Research and Treatments

Novel treatment combinations 0:01:32

Novel treatment combinations for FLT3-mutated AML

Phase II study 0:03:40

Phase II study of venetoclax and azacitidine vs induction chemotherapy in fit patients with AML

Magrolimab plus azacitidine 0:02:26

Magrolimab plus azacitidine in treatment-naïve AML

Phase I trial 0:01:33

Phase I trial results for oral azacitidine and venetoclax in R/R AML

Improving MDS management: 0:09:25

Improving MDS management: new targets, drug combinations, and personalized and cellular therapies

Higher-risk MDS and 0:57:07

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Current immune checkpoint 0:07:32

Current immune checkpoint inhibitor trials in AML/MDS

Virtual Round Table 0:33:39

Virtual Round Table with MD Anderson Part I - Dr. Naval Daver - New & Emerging Therapies #AML

TP53-Mutant AML: A 0:23:04

TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles

SELECT-AML-1: tamibarotene with 0:01:22

SELECT-AML-1: tamibarotene with venetoclax and azacitidine in patients with RARA-positive AML

New and emerging 0:06:53

New and emerging drug targets for older AML patients

What’s on the 0:33:55

What’s on the horizon for higher-risk MDS? An update on emerging novel agents?

AML: options after 0:02:12

AML: options after venetoclax-based regimen failure